Introduction {#s1}
============

Epidemiological studies in low-income countries suggested that immunization with certain vaccines can have non-specific effects (NSE) on all-cause morbidity and mortality among children ([@B1], [@B2]). Studies on NSE of vaccines were mostly conducted in low-income countries, but some findings were also replicated in high-income settings ([@B3]--[@B5]). One of the potential mechanisms discussed in the context of NSE is a non-specific modulation of the immune system. This has been supported by several studies showing that the uptake of live attenuated vaccines, such as Bacillus Calmette-Guérin (BCG) against tuberculosis and the vaccine against measles, has been associated with decreased morbidity and mortality to unrelated pathogens ([@B6]--[@B8]). In contrast to the observed beneficial NSE of live attenuated vaccines, DTP (an inactivated vaccine) seemed to induce negative NSE ([@B8]--[@B10]). The underlying immunological mechanisms of NSE are still unknown. Findings of animal studies and investigations on non-specific immunomodulation in adults indicated that infections affect the immune response also in a non-specific manner and alter the reaction toward unrelated subsequent infections ([@B7]). Furthermore, different factors, e.g., geographical location or immunization during pregnancy, can have NSE on the infants\' vaccine response ([@B11]). However, it remains unclear which pathways are involved in the modulation of the immune system; in particular, little is known regarding strengthening or weakening of antibody response to unrelated pathogens ([@B12]). Preferably, the effects should be studied in children, during the development of the immune system. However, assessing such effects on the antibody responses is complicated by the fact that not only vaccinations, but also infections during infancy and mothers\' exposures during pregnancy can potentially modulate antibody titers ([@B11]). Further, the time of exposure as well as accumulation of exposures might influence the immune response ([@B13]--[@B17]). The objective of our study was to investigate whether routine childhood vaccinations and the individual history of infections in the first 2 years of life as well as maternal exposures during pregnancy are associated with the modulation of antibody titer levels against unrelated pathogens at the age of 2 years.

Materials and Methods {#s2}
=====================

Study Population
----------------

We used data from the birth cohort "*Influence of Life-style factors on Development of the Immune System and Allergies in East and West Germany* (LISA)," which was described in detail elsewhere ([@B18], [@B19]); 3,094 healthy term newborns from four regions of Germany (Munich, Wesel, Leipzig, and Bad Honnef) were recruited between December 1997 and January 1999. Of these, 2,664 (86.1%) were followed up until the age of 2 years ([Figure 1](#F1){ref-type="fig"}). Their parents were asked to complete questionnaires every 6 months during the first 2 years of life. At the age of 2 years, blood samples were obtained from children and 12 antibody titers were measured. The LISA study was carried out in accordance with the recommendations of all relevant guidelines. The protocol was approved by the responsible ethic committees of all study centers (Bavarian Medical Council, University of Leipzig, Medical Council of North Rhine-Westphalia). All subjects gave written informed consent in accordance with the Declaration of Helsinki.

![Flow Chart of included children by investigated IgG titers. (1) Of these 2,661 completed the 2-years-questionnaire. (2) Of some children the serum was insufficient for detection of certain IgG titers. (3) One child with corresponding measles infection excluded.](fped-07-00254-g0001){#F1}

Exposure Variables---Infections and Vaccinations of the Child and Maternal Exposures During Pregnancy
-----------------------------------------------------------------------------------------------------

Based on self-reported data, we assessed exposure variables including vaccinations and infections of the child and maternal exposures during pregnancy. Information on experienced infections and obtained vaccinations of the children was collected retrospectively, approximately every 6 months using self-administered questionnaires. Parents were asked to consult the vaccination card when filling out the questionnaire and to record physician-diagnosed infections. To assess the influence of timing of the corresponding exposure, we classified each exposure of the child into four mutually exclusive categories: only in the first year, only in the second year, in both years, and neither in the first nor in the second year of life (reference group). We also combined different respiratory infections (pneumonia, bronchitis, obstructive or spastic bronchitis, and otitis media) into one variable since the risk of misclassification between these infections was assumed to be high. Similarly, vaccinations administered typically at the same time or as combinations were summarized into one variable \[measles, mumps, and rubella as MMR; diphtheria, tetanus, pertussis, polio, and *Haemophilus influenzae type b* (HIB) as DTPPHIB\]. The German standing committee on vaccinations (STIKO) provides recommendations about which vaccines should be given at which age ([@B20], [@B21]). The recommended vaccinations are not obligatory. Whether the vaccination is carried out or not is the responsibility of the parents. Data about socio-demographic and -economic factors, as well as maternal exposures during pregnancy including smoking, alcohol consumption, vaccinations, and infections of the mother, were also obtained through questionnaires. The participating mothers could indicate whether they have experienced any infection and whether they have received a vaccination during pregnancy (response options "yes," "no"). In addition, they could specify the type of infection/vaccination in a free-text field. Due to sample size limitations, we could not analyze different infections and vaccinations during pregnancy separately. We only included the dichotomized variable summarizing all reported infectious diseases \["infections during pregnancy" (yes/no)\], and similarly all received vaccinations during pregnancy \["vaccinations during pregnancy" (yes/no)\].

In total, we considered 19 different exposures including four routine childhood vaccinations (MMR, DTPPHIB, hepatitis B, BCG), 13 infectious diseases (any respiratory infection, pseudocroup, pertussis, roseola, chickenpox, diarrhea, thrush, urinary tract infection, worm infection, scarlet fever, mumps, measles, and rubella) as well as two maternal exposures during pregnancy (any vaccination and any infection during pregnancy).

Outcome Variables---IgG Antibody Titers
---------------------------------------

Blood samples of the participating children in the LISA study were obtained at the age of 2 years. Three antibody titers related mainly to vaccinations (IgG against measles, tetanus, and HIB) and nine titers predominately related to viral infections (adenovirus (ADV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), human parainfluenza virus 3 (hPIV-3), human respiratory syncytial virus (hRSV), herpes simplex virus (HSV), and influenza A and B) were measured ([Figure 1](#F1){ref-type="fig"}). Antibody titers were determined using routine enzyme-linked immunosorbent assays (ELISAs) or indirect immunofluorescence at the Institute for Virology of Leipzig University. In some cases, the serum was insufficient for the detection of certain IgG titer.

Statistical Analysis
--------------------

### Inclusion Criteria

For our analysis, we only included children with at least one of the twelve selected IgG titers measured. To ensure that the analyzed titers against measles, HIB, and tetanus were related to vaccinations, we included only seropositive cases for whom parents reported the corresponding vaccination and excluded children for whom parents reported the corresponding infection. We defined NSE as elevated/decreased titers of antibodies unrelated to the given infection/vaccination. To investigate only NSE, established associations between related infection/vaccination and the corresponding IgG titer were not assessed (such as the association between infections with roseola and HHV6 antibody titer, or infections with measles and measles antibody titer).

### Transformation of IgG Antibody Titers

Since for some IgG titers dilution series were reported, we considered the reciprocal values. The antibody titers were transformed using the Box-Cox method (bcskew0 function in Stata Version 12) ([@B22]) and subsequently z-transformed to ensure comparability of estimates across different analyses.

### Bivariate and Multivariable Association Analyses

First, we tested the association between each single of the 19 investigated exposures (four vaccinations, 13 infections, and two exposures during pregnancy) and each of the 12 transformed seropositive IgG titers separately using one-way analysis of variance (ANOVA). We did not apply classic correction methods for multiple testing, which are associated with several limitations in the context of exploratory analyses ([@B23]). Instead, we assessed whether more associations below a pre-defined *p*-value cut-off were observed than expected at random. For this purpose, we conducted a random permutation among the categories of the exposures and subsequently tested their association with IgG titers. This procedure was repeated 1,000 times. The median number of significant results (*p*-value \< 0.05) and the corresponding empirical 95% confidence intervals (95%-CI) were obtained and compared to the number of actually observed significant associations. Second, we included all exposure variables with *p* \< 0.25 from the bivariate analyses in a multivariable linear regression model for each of the 12 IgG titers in an exploratory analysis. We applied for each regression model a backward variable selection process (*p* \> 0.05 for removal of variables from the model based on Wald test). Sex of the child, maternal age at birth (as continuous variable), education level of the parents \[highest level received by either parent: low- without school-leaving certificate or lower secondary school certificate (\<10 years); intermediate- secondary school certificate (= 10 years); high- general qualification for university entrance (\>10 years)\] and region of recruitment (four levels: Munich, Leipzig, Bad Honnef and Wesel) were forced into the model for adjustment. In addition, if an association with smoking and alcohol consumption during pregnancy was observed within the bivariate analysis (*p* \< 0.25), the model was also adjusted for these variables. Initially, only cases with complete data were considered. In order to investigate potential bias due to missing values in exposure variables, we performed a sensitivity analysis using the missing indicator method (recoding missing values into an additional category "missing"). All analyses were performed with Stata for Windows, version 12 (StataCorp, College Station, Texas).

Results {#s3}
=======

Description of the Study Population, Exposures, and Analyzed Titers
-------------------------------------------------------------------

Two-thirds of the participants (*n* = 2,123) had at least one available IgG antibody titer at the age of 2 years out of the 12 selected ([Table 1](#T1){ref-type="table"}). There were only minor differences in baseline characteristics between those with available antibody titers and those without. Depending on the type of vaccination, data were missing for 13--50% of the children ([Table 2](#T2){ref-type="table"}). Taking missing values into account, 10.6% reported that their children received a BCG vaccination in the first 2 years of age (rarely reported vaccination); 51.0% of the children received a vaccination against MMR while 59.4% a vaccination against hepatitis B, and 86.4% of the children were vaccinated against DTPPHIB (often reported vaccination) ([Table 2](#T2){ref-type="table"}). In case of the MMR vaccine, we categorized all those who did not report all three MMR components (*n* = 326) as "missing," since we could not distinguish between reporting errors and decision to vaccinate only selected vaccines. In contrast to self-reported vaccinations, the amount of missing data for infectious diseases was much lower (up to 6.6%). Infection rates displayed three patterns as well: rarely reported diseases (\<5%) were e.g., scarlet fever or mumps; common childhood infections (thrush or roseola) were reported by up to 30%; and more frequent diseases such as diarrhea and respiratory infections were reported by over 50%. Several infections were only recorded in the second year of life (e.g., scarlet fever). 13.3% of the expectant mothers experienced infections, and 15.4% were vaccinated during pregnancy. The number of children with seropositive IgG titers varied across all 12 analyzed titers ([Figure 1](#F1){ref-type="fig"} and [Supplementary Table S1](#SM1){ref-type="supplementary-material"}). Of the 1,428 children with evidence of anti-measles seropositivity, 85.7% (*n* = 1,249) reported to have ever been vaccinated against measles. The remaining children were excluded from the analysis. Additionally, one child, for whom measles infection and vaccination was reported, was excluded; thus, we studied only vaccine-induced measles antibodies. For anti-tetanus and anti-HIB seropositive children, 99% reported to have received the corresponding vaccination. About 80% were seropositive for HHV-6. Between 15 and 60% of the children were seropositive for IgG antibodies against ADV, EBV, hPIV-3, hRSV, CMV, and influenza A. In \<10% of the children, seropositive IgG titers against HSV and influenza B were observed.

###### 

Baseline characteristics of participants in the LISA study.

  **Characteristics**                                               **All participants *N* = 3,094**   **Participants with an available IgG titer *N* = 2,123[^a^](#TN1){ref-type="table-fn"}**
  ----------------------------------------------------------------- ---------------------------------- ------------------------------------------------------------------------------------------
  Sex of child, % *(n/N)*                                                                              
    Female                                                          48.8 (1,510/3,094)                 47.5 (1,009/2,123)
    Male                                                            51.2 (1,584/3,094)                 52.5 (1,114/2,123)
  Year of birth, % *(n/N)*                                                                             
    1997                                                            1.3 (41/3,094)                     1.5 (31/2,123)
    1998                                                            92.0 (2,845/3,094)                 92.0 (1,953/2,123)
    1999                                                            6.7 (208/3,094)                    6.6 (139/2,123)
  Median age of the mother at birth, y *(Q1;Q3)*                                                       
                                                                    31 (28/34)                         31 (29/34)
  Education of parents, % *(n/N)*[^b^](#TN2){ref-type="table-fn"}                                      
    Low                                                             6.2 (188/3,057)                    4.2 (88/2,102)
    Intermediate                                                    29.6 (906/3,057)                   27.4 (576/2,102)
    High                                                            64.2 (1,963/3,057)                 68.4 (1,438/2,102)
  Study location, % *(n/N)*                                                                            
    Munich                                                          47.3 (1,464/3,094)                 48.5 (1,029/2,123)
    Leipzig                                                         31.5 (976/3,094)                   30.5 (647/2,123)
    Bad Honnef                                                      9.9 (306/3,094)                    11.2 (238/2,123)
    Wesel                                                           11.3 (348/3,094)                   9.8 (209/2,123)
  Provided questionnaires, % *(n/N)*                                                                   
    Birth questionnaire                                             100.0 (3,094/3,094)                100.0 (2,123/2,123)
    Half-year questionnaire *(0--5 months of age)*                  91.3 (2,825/3,094)                 99.1 (2,104/2,123)
    1-year questionnaire *(6--11 months of age)*                    88.4 (2,734/3,094)                 97.9 (2,078/2,123)
    One-and-half year questionnaire *(12--18 months of age)*        87.5 (2,707/3,094)                 98.2 (2,085/2,123)
    2-years questionnaire *(19--24 months of age)*                  86.0 (2,661/3,094)                 99.5 (2,113/2,123)

*Q1, first quartile (25%); Q3, third quartile (75%)*.

*Children included with at least one available IgG titer of 12 selected antibody titers*.

*Low, without school-leaving certificate or lower secondary school certificate (\<10 years); intermediate, secondary school certificate (= 10 years); high, general qualification for university entrance (\>10 years)*.

###### 

Exposure to vaccinations and infections during first 2 years of life as well as during pregnancy of participants in the LISA study.

  **Reported infections**                                   **Only first year[^a^](#TN3){ref-type="table-fn"} % (*n*)**               **Only second year[^a^](#TN3){ref-type="table-fn"} % (*n*)**               **Both years[^a^](#TN3){ref-type="table-fn"} % (*n*)**               **No infection[^a^](#TN3){ref-type="table-fn"} % (*n*)**                 **Missing[^a^](#TN3){ref-type="table-fn"} % (*n*)**
  --------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------ -----------------------------------------------------
  Respiratory infection[^b^](#TN4){ref-type="table-fn"}     5.8 (123)                                                                 16.8 (356)                                                                 69.7 (1,480)                                                         4.9 (104)                                                                2.8 (60)
  Pseudocroup                                               2.0 (43)                                                                  7.4 (157)                                                                  1.5 (32)                                                             83.2 (1,767)                                                             5.8 (124)
  Pertussis                                                 0.3 (7)                                                                   0.2 (4)                                                                    0.1 (2)                                                              93.6 (1,988)                                                             5.8 (122)
  Roseola                                                   13.2 (280)                                                                14.2 (302)                                                                 4.7 (100)                                                            61.2 (1,300)                                                             6.6 (141)
  Chickenpox                                                5.4 (115)                                                                 11.3 (239)                                                                 0.7 (15)                                                             77.1 (1,637)                                                             5.5 (117)
  Diarrhea with or without fever                            11.4 (242)                                                                29.2 (620)                                                                 19.0 (404)                                                           35.1 (745)                                                               5.3 (112)
  Thrush in the mouth or diaper area                        19.5 (413)                                                                10.2 (217)                                                                 8.6 (183)                                                            56.6 (1,201)                                                             5.1 (109)
  Urinary tract infection[^c^](#TN5){ref-type="table-fn"}   --                                                                        2.7 (57)                                                                   --                                                                   94.2 (2,000)                                                             3.1 (66)
  Worm infection                                            0                                                                         0.3 (6)                                                                    0                                                                    94.5 (2,007)                                                             5.2 (110)
  Scarlet fever[^c^](#TN5){ref-type="table-fn"}             --                                                                        2.4 (51)                                                                   --                                                                   94.8 (2,012)                                                             2.8 (60)
  Mumps[^d^](#TN6){ref-type="table-fn"}                     --                                                                        0.1 (3)                                                                    --                                                                   98.9 (2,100)                                                             0.9 (20)
  Measles[^d^](#TN6){ref-type="table-fn"}                   --                                                                        0.1 (2)                                                                    --                                                                   99.0 (2,101)                                                             0.9 (20)
  Rubella[^d^](#TN6){ref-type="table-fn"}                   --                                                                        0.5 (11)                                                                   --                                                                   98.5 (2,092)                                                             0.9 (20)
  **Obtained vaccinations against**                         **Only first year**[^a^](#TN3){ref-type="table-fn"} **% (*****n*****)**   **Only second year**[^a^](#TN3){ref-type="table-fn"} **% (*****n*****)**   **Both years**[^a^](#TN3){ref-type="table-fn"} **% (*****n*****)**   **No vaccination**[^a^](#TN3){ref-type="table-fn"} **% (*****n*****)**   **Missing % (*****n*****)**
  Tuberculosis (BCG)                                        8.9 (189)                                                                 0.5 (10)                                                                   1.2 (25)                                                             39.1 (831)                                                               50.3 (1,068)
  DTPPHIB[^e^](#TN7){ref-type="table-fn"}                   12.4 (264)                                                                1.2 (26)                                                                   72.8 (1,545)                                                         0.7 (15)                                                                 12.9 (273)
  Hepatitis B                                               11.2 (238)                                                                5.0 (106)                                                                  43.2 (916)                                                           14.9 (317)                                                               25.7 (546)
  MMR[^f^](#TN8){ref-type="table-fn"}                       1.5 (32)                                                                  45.4 (964)                                                                 4.1 (86)                                                             16.2 (344)                                                               32.8 (697)[^g^](#TN9){ref-type="table-fn"}
  **Maternal exposures[^h^](#TN10){ref-type="table-fn"}**   **Ever during pregnancy % (*****n*****)**                                 **Never during pregnancy % (*****n*****)**                                 **Missing % (*****n*****)**                                                                                                                   
  Vaccination                                                                                                                         15.4 (326)                                                                                                                                      84.4 (1,791)                                                             0.3 (6)
  Infection                                                                                                                           13.3 (283)                                                                                                                                      86.4 (1,834)                                                             0.3 (6)

*Only first year, only children vaccinated/infected within the first year of age; Only second year, only children vaccinated/infected within the second year of age; Both years, only children vaccinated/infected during both, first and second year of age; No infection/vaccination, no vaccination/infection in the first 2 years of life; Missing, missing values*.

*Includes pneumonia, otitis media, obstruct or spastic bronchitis, respiratory diseases and bronchitis*.

*Only asked in children aged 12--24 months*.

*Only asked in children aged 19--24 months*.

*Includes vaccinations against diphtheria, tetanus, polio, pertussis, and Haemophilus influenzae type b (HIB)*.

*Includes vaccinations against mumps, measles, and rubella*.

Children with incomplete data on vaccination against all three, mumps, measles and rubella, were classified as "Missing."

*Dichotomous-categorized variables*.

Bivariate Association Analyses
------------------------------

Overall, we identified 21 significant associations between exposures and studied antibody titers ([Table 3](#T3){ref-type="table"}). Based on permutation, 11 (95%-CI: 6, 17) spurious associations could be expected at a significance level of 5%. When considering missing values as additional category in the bivariate analysis, we observed 24 significant associations ([Table 4](#T4){ref-type="table"}), 16 associations were observed in both analyses.

###### 

Bivariate associations between infections, vaccinations, exposures during pregnancy, and IgG antibody titers of participants in the LISA study (*p*-values for *F*-test from ANOVA).

  **Exposures**                                                       **Antibody titer[^a^](#TN11){ref-type="table-fn"}**                                                                                                                                                                                                                                               
  ------------------------------------------------------------------- ----------------------------------------------------- ----------- ----------- ----------- ---------------------------------------- ---------------------------------------- ----------- ---------------------------------------- ---------------------------------------- ----------- ----------- -------------
  **Reported infections[^b^](#TN12){ref-type="table-fn"}**                                                                                                                                                                                                                                                                                                              
  Respiratory infection[^c^](#TN13){ref-type="table-fn"}              0.686                                                 0.705       0.313       0.914       0.585[^i^](#TN19){ref-type="table-fn"}   0.309[^i^](#TN19){ref-type="table-fn"}   0.091       0.135[^i^](#TN19){ref-type="table-fn"}   0.552[^i^](#TN19){ref-type="table-fn"}   0.222       n.a.        **0.040**
  Pseudocroup                                                         0.256                                                 0.808       0.192       0.324       0.849[^i^](#TN19){ref-type="table-fn"}   0.381[^i^](#TN19){ref-type="table-fn"}   0.947       0.622[^i^](#TN19){ref-type="table-fn"}   0.271[^i^](#TN19){ref-type="table-fn"}   0.587       **0.026**   0.735
  Pertussis                                                           0.611                                                 0.732       0.370       0.341       0.624                                    0.418                                    0.947       0.503                                    --                                       0.206       0.113       0.251
  Roseola                                                             0.254                                                 0.658       0.263       n.a.        0.620                                    0.976                                    0.312       0.435                                    0.656                                    0.827       0.566       0.798
  Chickenpox                                                          0.732                                                 0.138       0.347       0.818       0.175                                    0.522                                    0.361       0.575                                    0.641                                    **0.042**   0.416       0.358
  Diarrhea                                                            0.937                                                 0.250       0.278       0.245       0.675                                    0.763                                    0.497       0.280                                    0.711                                    0.253       0.601       0.554
  Thrush in the mouth or diaper area                                  0.219                                                 0.817       0.526       **0.011**   0.697                                    0.383                                    0.414       0.091                                    0.742                                    0.191       0.932       0.154
  Urinary tract infection[^d^](#TN14){ref-type="table-fn"}            0.792                                                 0.864       0.352       0.913       0.427                                    0.863                                    **0.001**   0.356                                    0.481                                    0.308       0.386       0.908
  Worm infection                                                      --                                                    0.667       0.919       0.782       0.658                                    0.273                                    0.448       0.238                                    --                                       0.892       0.712       0.813
  Scarlet fever[^d^](#TN14){ref-type="table-fn"}                      0.946                                                 0.447       0.350       0.345       0.520                                    0.592                                    0.970       0.774                                    0.548                                    0.206       0.506       0.231
  Measles[^e^](#TN15){ref-type="table-fn"}                            --                                                    **0.020**   --          0.422       0.187                                    0.271                                    --          --                                       --                                       n.a.        0.963       0.068
  Mumps[^e^](#TN15){ref-type="table-fn"}                              0.940                                                 0.362       0.082       0.565       0.181                                    --                                       0.819       0.408                                    --                                       0.054       0.946       0.726
  Rubella[^e^](#TN15){ref-type="table-fn"}                            **0.012**                                             0.828       0.760       0.623       0.925                                    **0.042**                                0.299       0.785                                    --                                       0.538       0.979       0.200
  **Obtained vaccination against[^b^](#TN12){ref-type="table-fn"}**                                                                                                                                                                                                                                                                                                     
  Tuberculosis                                                        **0.044**                                             0.231       0.605       **0.020**   **0.001**                                0.538                                    0.914       0.052                                    0.948                                    0.054       0.509       0.051
  DTPPHIB[^f^](#TN16){ref-type="table-fn"}                            0.511                                                 0.541       0.935       0.727       0.834                                    0.121                                    0.442       0.194                                    0.988                                    **0.003**   *n.a*.      *n.a*.
  Hepatitis B                                                         0.144                                                 0.555       0.799       0.431       0.851                                    0.555                                    0.863       0.656                                    0.204                                    **0.045**   **0.003**   **\<0.001**
  MMR                                                                 0.229                                                 0.548       0.425       0.402       0.240                                    0.505                                    0.937       0.542                                    0.902                                    n.a.        **0.020**   **0.032**
  **Exposures during pregnancy[^g^](#TN17){ref-type="table-fn"}**                                                                                                                                                                                                                                                                                                       
  Vaccinations[^g^](#TN17){ref-type="table-fn"}                       0.554                                                 0.672       0.509       **0.005**   0.220                                    0.356                                    0.347       0.283                                    0.901                                    0.060       **0.022**   0.435
  Infections[^g^](#TN17){ref-type="table-fn"}                         0.557                                                 0.998       **0.046**   0.803       **0.027**                                0.274                                    0.362       0.833                                    0.323                                    0.397       0.190       0.543

*ADV, adenovirus; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV-6, human herpesvirus 6; HIB, Haemophilus influenzae type b; hPIV-3, human parainfluenza virus 3; hRSV, human respiratory syncytial virus; HSV, herpes simplex virus; MMR, combine vaccination against mumps measles and rubella; --, No p-value calculated, since no observation in this category; n.a., not analyzed, since only non-specific effects are analyzed; bold values indicates p \<0.05*.

*Normalized and standardized antibody titers of children; reported p-value by ANOVA*.

*Four categories for exposures: only in first year, only in second year, in both years, and in neither of the 2 years of age (reference group); respectively for reported infectious disease or obtained vaccination*.

*Includes pneumonia, otitis media, obstruct or spastic bronchitis, respiratory diseases, and bronchitis*.

*Only asked in children aged 12--24 months*.

*Only asked in children aged 19--24 months*.

*Includes vaccination against diphtheria, tetanus, polio, pertussis, and HIB*.

*Vaccination/infection ever during pregnancy vs. vaccination/ infection never during pregnancy (dichotomized coded)*.

*Only IgG titers of children with corresponding vaccination; children with corresponding infection were excluded*.

*While the specific viruses can cause respiratory infections and lead to a pseudocroup, they are not their single, or most common cause, and therefore, the exposure were kept in the analysis (none displayed a significant association with the respective IgG titer)*.

###### 

Bivariate associations between infections, vaccinations, exposures during pregnancy including missing values, and IgG antibody titers of participants in the LISA study (*p*-values for *F*-test from ANOVA).

  **Exposures**                                                       **Antibody titer[^a^](#TN20){ref-type="table-fn"}**                                                                                                                                                                                                                                           
  ------------------------------------------------------------------- ----------------------------------------------------- ------- ----------- ----------- ---------------------------------------- ---------------------------------------- ----------- ---------------------------------------- ---------------------------------------- ----------- ----------- -------------
  **Reported infections[^b^](#TN21){ref-type="table-fn"}**                                                                                                                                                                                                                                                                                                          
  Respiratory infection[^c^](#TN22){ref-type="table-fn"}              0.696                                                 0.801   0.339       0.419       0.190[^i^](#TN28){ref-type="table-fn"}   0.405[^i^](#TN28){ref-type="table-fn"}   0.154       0.179[^i^](#TN28){ref-type="table-fn"}   0.656[^i^](#TN28){ref-type="table-fn"}   0.321       n.a.        **0.020**
  Pseudocroup                                                         0.158                                                 0.914   0.279       0.202       0.664[^i^](#TN28){ref-type="table-fn"}   0.340[^i^](#TN28){ref-type="table-fn"}   0.818       0.774i                                   0.441[^i^](#TN28){ref-type="table-fn"}   0.497       **0.013**   0.055
  Pertussis                                                           0.368                                                 0.866   0.558       0.415       0.273                                    0.165                                    0.175       0.669                                    0.578                                    0.079       **0.038**   **0.012**
  Roseola                                                             0.355                                                 0.792   0.277       *n.a*.      0.283                                    0.524                                    0.245       0.568                                    0.794                                    0.547       0.623       0.354
  Chickenpox                                                          0.315                                                 0.219   0.462       0.836       0.113                                    0.151                                    0.121       0.736                                    0.734                                    **0.029**   0.397       0.142
  Diarrhea                                                            0.787                                                 0.338   0.404       0.171       0.252                                    0.615                                    0.529       0.423                                    0.824                                    0.391       0.397       **0.036**
  Thrush in the mouth or diaper area                                  0.058                                                 0.693   0.686       **0.014**   0.442                                    0.512                                    0.438       0.158                                    0.757                                    0.201       0.399       **0.012**
  Urinary tract infection[^d^](#TN23){ref-type="table-fn"}            0.937                                                 0.817   0.409       0.981       0.727                                    0.739                                    **0.001**   0.192                                    0.667                                    0.173       0.459       0.194
  Worm infection[^d^](#TN23){ref-type="table-fn"}                     0.706                                                 0.886   0.925       0.411       0.414                                    0.350                                    **0.011**   0.496                                    0.880                                    0.321       0.344       0.099
  Scarlet fever[^d^](#TN23){ref-type="table-fn"}                      0.230                                                 0.642   0.572       0.628       0.693                                    0.862                                    0.369       0.508                                    0.592                                    0.353       0.256       0.116
  Measles[^e^](#TN24){ref-type="table-fn"}                            0.505                                                 0.062   0.389       0.705       0.188                                    0.502                                    0.766       0.187                                    --                                       n.a.        0.613       0.115
  Mumps[^e^](#TN24){ref-type="table-fn"}                              0.799                                                 0.615   0.153       0.825       0.184                                    0.683                                    0.933       0.298                                    --                                       **0.024**   0.612       0.571
  Rubella[^e^](#TN24){ref-type="table-fn"}                            **0.035**                                             0.960   0.660       0.868       0.449                                    0.117                                    0.569       0.565                                    --                                       0.225       0.828       0.300
  **Obtained vaccination against[^b^](#TN21){ref-type="table-fn"}**                                                                                                                                                                                                                                                                                                 
  Tuberculosis                                                        0.108                                                 0.290   0.751       **0.010**   **0.001**                                0.590                                    0.978       **0.033**                                0.447                                    **0.023**   0.622       0.107
  DTPPHIB[^f^](#TN25){ref-type="table-fn"}                            0.568                                                 0.620   0.698       0.667       0.854                                    0.079                                    0.647       0.279                                    0.981                                    **0.005**   n.a.        n.a.
  Hepatitis B                                                         0.129                                                 0.671   0.463       0.555       0.783                                    0.661                                    0.931       0.799                                    0.166                                    **0.037**   **0.008**   **\<0.001**
  MMR                                                                 0.299                                                 0.709   0.526       0.559       0.313                                    0.669                                    0.933       0.367                                    0.078                                    n.a.        **0.041**   0.065
  **Exposures during pregnancy[^g^](#TN26){ref-type="table-fn"}**                                                                                                                                                                                                                                                                                                   
  Vaccinations                                                        0.668                                                 0.806   0.509       **0.017**   0.220                                    0.651                                    0.347       0.536                                    0.901                                    0.144       0.072       0.698
  Infections                                                          0.669                                                 0.944   **0.026**   0.800       **0.027**                                0.501                                    0.583       0.953                                    0.323                                    0.464       0.389       0.630

*ADV, adenovirus; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV-6, human herpesvirus 6; HIB, Haemophilus influenzae type b; hPIV-3, human parainfluenza virus 3; hRSV, human respiratory syncytial virus; HSV, herpes simplex virus; MMR, combined vaccination against mumps, measles, and rubella; --, No p-value calculated, since no observation in this category; n.a., not available, since only non-specific effects are analyzed; bold values indicates p \<0.05*.

*Normalized and standardized antibody titers of children; reported p-value by ANOVA*.

*Five categories for exposures: only in first year, only in second year, in both years, missing values, and in neither of the 2 years of age (reference group); respectively for reported infectious disease or obtained vaccination*.

*Includes pneumonia, otitis media, obstruct or spastic bronchitis, respiratory diseases, and bronchitis*.

*Only asked in children aged 12--24 months*.

*Only asked in children aged 19--24 months*.

*Includes vaccination against diphtheria, tetanus, polio, pertussis, and HIB*.

*Vaccination/infection ever during pregnancy vs. vaccination/infection never during pregnancy (dichotomized coded)*.

*Only IgG titers of children with corresponding vaccination; children with corresponding infection were excluded*.

*While the specific viruses can cause respiratory infections and lead to a pseudocroup, they are not their single or most common cause, and therefore, the exposure were kept in the analysis (none displayed a significant association with the respective IgG titer)*.

Multivariable Analyses of Association
-------------------------------------

Multivariable regression models with evidence for an association between exposure variables and the respective titer after backward selection are displayed in [Table 5](#T5){ref-type="table"}; each outcome titer was analyzed in a separate model. The reported regression coefficients are presented in units of standard deviation of the standard normal distribution; they are thus comparable across the models in terms of magnitude. Because of the different number of incomplete cases for specific variables, the sample size differs across the models. For five IgG antibody titers (ADV, CMV, EBV, influenza A, and influenza B) no significant associations remained after backwards selection. For seven antibody titers, there were in total 10 significant associations with exposure variables. Chickenpox during the first year of life (i.e., prior to measles vaccination) was associated with an increased measles IgG titer compared to children who did not experience chickenpox during the first 2 years. Thrush during the second year of life was associated with an elevated HHV-6 IgG titer. Vaccinations against hepatitis B and tuberculosis during the first year of life were associated with decreased tetanus IgG titer level when compared to children who received neither vaccination. Vaccination against MMR was associated with an increased anti-HIB IgG titer. Since the number of individuals in the actual reference group "children with no DTPPHIB vaccination" was too low, we considered the category "DTPPHIB vaccination in both years" as the reference group. Accordingly, children vaccinated against DTPPHIB only during the first year had a lower IgG measles vaccine-related titer compared to children vaccinated against DTPPHIB during both years. BCG vaccine in the first year of life was associated with an increased hRSV IgG titer. Infections during pregnancy were associated with reduced hRSV IgG titers. For two antibody titers we detected significant associations (hPIV-3 and rubella during the year of life; HSV and urinary tract infection in the second year of life) with a low number of observations in the respective category (*n* = 2).

###### 

Adjusted associations between vaccinations, infections, and exposures during pregnancy and IgG titers of participants in the LISA study[^\*^](#TN29){ref-type="table-fn"}.

  **Antibody titer (*n*)[^a^](#TN30){ref-type="table-fn"}**                                **Exposure (*n*)**                                                  **Time[^b^](#TN31){ref-type="table-fn"}**                   **Regression coefficient[^c^](#TN32){ref-type="table-fn"}**   **95%-CI**       ***p*-value**
  ---------------------------------------------------------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------- ---------------- ---------------
  **Measles**^**[d](#TN33){ref-type="table-fn"},[e](#TN34){ref-type="table-fn"}**^ (599)   Chickenpox (31)                                                     1\.                                                         0.441                                                         0.082, 0.799     0.016
                                                                                           Chickenpox (65)                                                     2\.                                                         0.218                                                         −0.035, 0.472    0.092
                                                                                           Chickenpox ([@B4])                                                  1\. and 2.                                                  −0.920                                                        −1.887, 0.046    0.062
                                                                                           Vaccination against DTPPHIB[^f^](#TN35){ref-type="table-fn"} (85)   1\.                                                         −0.367                                                        −0.593, −0.141   0.002
                                                                                           Vaccination against DTPPHIB[^f^](#TN35){ref-type="table-fn"} (1)    2\.                                                         −0.441                                                        −2.363, 1.481    0.652
  **Tetanus**^**[d](#TN33){ref-type="table-fn"},[e](#TN34){ref-type="table-fn"}**^ (842)   Vaccination against hepatitis B (131)                               1\.                                                         −0.323                                                        −0.550, 0.097    0.005
                                                                                           Vaccination against hepatitis B (68)                                2\.                                                         0.065                                                         −0.198, 0.328    0.629
                                                                                           Vaccination against hepatitis B (414)                               1\. and 2.                                                  0.167                                                         0.005, 0.339     0.057
                                                                                           Vaccination against tuberculosis (139)                              1\.                                                         −0.282                                                        −0.478, −0.087   0.005
                                                                                           Vaccination against tuberculosis (5)                                2\.                                                         −0.708                                                        −1.559, 0.143    0.103
                                                                                           Vaccination against tuberculosis (12)                               1\. and 2.                                                  −0.250                                                        −0.815, 0.314    0.385
  **HIB**^**[d](#TN33){ref-type="table-fn"},[e](#TN34){ref-type="table-fn"}**^ (968)       Vaccination against MMR (23)                                        1\.                                                         0.259                                                         −0.194, 0.713    0.262
                                                                                           Vaccination against MMR (700)                                       2\.                                                         0.202                                                         0.038, 0.367     0.016
                                                                                           Vaccination against MMR (61)                                        1\. and 2.                                                  −0.017                                                        −0.314, 0.280    0.909
  **HHV-6** (816)                                                                          Thrush (169)                                                        1\.                                                         0.020                                                         −0.153, 0.193    0.818
                                                                                           Thrush (92)                                                         2\.                                                         0.359                                                         0.140, 0.579     0.001
                                                                                           Thrush (71)                                                         1\. and 2.                                                  0.037                                                         −0.209, 0.283    0.770
  **hRSV** (483)                                                                           Vaccination against tuberculosis (83)                               1\.                                                         0.382                                                         0.120, 0.645     0.004
                                                                                           Vaccination against tuberculosis (1)                                2\.                                                         −1.429                                                        −3.389, 0.532    0.153
                                                                                           Vaccination against tuberculosis (8)                                1\. and 2.                                                  −0.054                                                        −0.773, 0.666    0.883
                                                                                           Infection (65)                                                      During pregnancy vs. not[^g^](#TN36){ref-type="table-fn"}   −0.279                                                        −0.545, −0.014   0.039

*HHV-6, human herpesvirus 6; HIB: Haemophilus influenzae type b; hRSV, human respiratory syncytial virus; MMR, combine vaccination against mumps measles and rubella*.

*For two antibodies (hPIV-3 and HSV) the final model had \<10 observations in the exposed group; these significant results are not presented*.

*Multivariable linear regression, backward selection of independent variables of normalized and standardized IgG antibody titers; only antibody titers were considered with evidence of seropositivity*.

*1., exposure only in first year of age; 2., exposure only in second year of age; 1. and 2., exposure only in first 2 years of age; reference group: children with no corresponding exposure in the first 2 years of age*.

*Regression coefficients are presented in units of standard deviation of the standard normal distribution; adjusted for sex of child, age of the mother at birth, education level of the parents, and study center*.

*Only IgG titers of vaccinated children; children with corresponding infection were excluded*.

*In addition adjusted for smoking during pregnancy*.

*DTPPHIB: vaccination against diphtheria, tetanus, pertussis, HIB and polio; no estimator for "no vaccination" exist, since no measles antibody titer could be detected, accordingly the category "vaccination in both years (1. and 2.)" was selected as reference group*.

*Binary coded*.

In the sensitivity analysis with missing indicator method, we observed 12 significant associations involving nine of the 12 IgG titers ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}). Apart from three associations (anti-hRSV titer and infection during pregnancy; anti-tetanus titer and vaccination with BCG; anti-HIB titer and vaccination against MMR), all findings from the primary analysis could be reproduced. Moreover, we found additional significant associations for the IgG titers against ADV, EBV, HIB, influenza A, and HHV-6.

Discussion {#s4}
==========

Using data from a large birth cohort study, we analyzed the association between maternal exposures during pregnancy and infections/vaccinations of the child in the first 2 years of life on the one side and 12 IgG antibody titers measured at the age of 2 years on the other side.

Modulation of IgG antibody titer levels could be a potential mechanism of the NSE of vaccinations described in previous research. The number of identified significant associations between specific exposures and antibody titers exceeded the number expected due to multiple testing only. Some of our findings were in line with previous studies, whereas others have not been described before. In the following, we compare our findings with the literature.

In our study, BCG vaccination, which was mostly given during the first year of life, was associated with a significant increase of hRSV IgG titer compared to children not vaccinated against BCG. Recent reviews concluded that live attenuated vaccines such as BCG, have beneficial NSE on the neonatal mortality ([@B8], [@B10]). Furthermore, it has been reported that BCG was associated with a lower risk of acute lower respiratory infections in children in a study based on Demographic and Health Surveys from 19 developing countries ([@B27]), which was confirmed in an epidemiological study conducted in a developed country ([@B4]). Findings in a study in Guinea-Bissau ([@B28]) indicated that BCG vaccination has a specific protective effect against acute lower respiratory infections caused by hRSV, with the effect being most marked in girls. The beneficial NSE of BCG vaccination was already used to successfully improve the T~H~1 cell immunity against RSV by recombinant BCG strains expressing RSV-proteins in mice ([@B29]). The authors assumed that BCG expressing RSV antigen is a potential candidate for a new vaccine to prevent hRSV infection during infancy.

In contrast to the observed beneficial NSE on hRSV titer, BCG-vaccinated children in the first year of life had a lower tetanus IgG antibody titer compared to non-BCG immunized children in our study. However, this effect disappeared in the analysis including missing data, thus suggesting that the initially observed association was possibly an artifact. In agreement with this observation, Ota et al. ([@B12]) showed no significant differences in the antibody response toward tetanus toxoid in BCG-vaccinated newborns compared to not vaccinated ones in a randomized trial ([@B12]). This finding is also in line with a study on Australian infants as well as with the recent investigation of Nissen et al. ([@B24]) in Danish neonates ([@B24], [@B30]).

We also observed a non-specific association between MMR vaccination at the age of 1 year and elevated anti-HIB IgG titer at the age of two. However, this association disappears in our sensitivity analysis suggesting that this effect could also be an artifact. For DTP vaccine, a recent review concluded that it can possibly have negative effects on mortality ([@B10]) and a follow-up analysis argued that the evidence is even stronger ([@B9]). We were not able to examine NSE of DTP: in comparison to non-vaccinated children since only 0.7% of the children were not vaccinated against DTPPHIB ([Table 2](#T2){ref-type="table"}). In addition, as we have grouped vaccines, which were typically administrated at the same time, we could not assess the effect of DTP alone. Instead, we considered "vaccination in both years (1. and 2.)" as reference category. We observed lower measles antibody titres in children vaccinated against DTPPHIB in the first year only compared to children vaccinated in both years. This could suggest that effects differ dependent on whether DTPPHIB vaccines are given only before MMR vaccine or before and after. de Bree et al. discussed that the sequence of vaccinations may play a role, and that the most recently obtained vaccination affects the immune response non-specifically ([@B8]).

Furthermore, we observed higher vaccination-related anti-measles IgG titers in children who experienced chickenpox during the first year of life, while chickenpox at older age did not affect the anti-measles titer levels. The observed effect could be explained by either a specific sensitive phase of the development of immunity or the fact that exposure to chickenpox preceding vaccination can be more important than exposure following vaccination. The latter explanation would suggest that modulation of the initial immune response is the mechanism rather than enhancement of already existing IgG levels due to chickenpox infection.

In previous studies, the effects of infections during pregnancy on the immune response of infants were primarily investigated for severe infections, like human immunodeficiency virus (HIV) or malaria ([@B11]). While we did not observe any NSE for vaccinations during pregnancy, we observed an association between infections during pregnancy and a decreased hRSV IgG antibody titer in the multivariable analysis. However, the initially observed association was no longer significant in the analysis including missing data. Accordingly, this finding could also be an artifact. This part of the analysis was only exploring an unspecific hypothesis regarding recent exposure to vaccination or infections---not the lifetime exposure of the mother, which could also result in passive immunity in the newborn.

The underlying immunological mechanisms of NSE have not yet been clarified. So far, two main explanations have been discussed concerning the NSE of certain vaccines; one is related to the T-cell-mediated cross-reactivity (heterologous immunity) relating the observed NSE of vaccinations to the encoded antigens, which induce a cross-reaction with other pathogens ([@B6], [@B7], [@B26], [@B31]). This mechanism can include modulation of antibody titers. The second explanation assumes that the beneficial effects might base on epigenetic reprogramming of innate immune cells, termed the *trained immunity*. Evidence is growing that adaptive features of the innate immune system protect against infections independently from specific T and B cells of the adaptive immune system and seem to exhibit an immunological memory ([@B6], [@B25], [@B32]--[@B34]). These two concepts explain how a pathogen or vaccination can induce non-specific immune response toward an unrelated pathogen, which might lead to the either beneficial or adverse NSE on subsequent infections. While our findings seem to support the first explanation, innate immunity could also be involved in increased antibody titers via e.g., increased maturation or activation of antigen presenting cells. There can be different explanations of this phenomenon, but the available data do not allow more in-depth analyses. However, as Gil et al. ([@B7]) discussed, epidemiological studies suggest that the sequence of vaccinations or infections may have an impact on the immune response toward subsequent unrelated infections.

Strengths and Limitations
-------------------------

Since infections and vaccinations were self-reported retrospectively, misclassification is possible. However, parents were asked to consult the children\'s vaccination cards. In addition, we included only infections reported as diagnosed by the physician, to reduce the risk of misclassification. Still, there is the possibility of misclassification of infections with similar symptoms (all respiratory infections were reclassified into a single variable as they bore the highest risk of misclassification). On the other side, infections for which parents did not seek medical consultation were not considered. In some cases, sub-clinical or unreported infections could affect vaccine-related titers for the same diseases (more likely for HIB, than for measles for example). Some epidemiological studies indicated different NSE of the BCG-vaccine depending on early or late administration during the neonatal period \[review in ([@B8])\], however, we could not assess this issue due to insufficient data on timing of BCG vaccination.

Since not all participating parents answered each question regarding infections and obtained vaccinations, this resulted in low numbers of observations for some analyses if seropositivity was rare as well. In these cases, we had low statistical power and might have missed true associations, e.g., for the antibody titers hPIV-3 and HSV with low number of observations in the respective groups (*n* = 2). To ensure that no systematic bias was caused by removal of incomplete data, we performed additional bivariate as well as multivariable analyses including missing values as a separate category. Since the results of the complete case analyses were mostly reproduced in the missing indicator method analyses, it can be suggested that the findings were largely robust.

For investigating NSE of exposure on the immune response of already experienced infections, we only considered seropositive children for each IgG titer. It is possible, however, that children with low immune response just below the threshold were excluded even though an immune response existed. In addition, for some children an analysis for certain IgG titers was not possible, since the amount of blood in the sample was insufficient. To obtain comparable values, we transformed and standardized the IgG antibody titers; however, obtaining normal distribution was not possible for all of them. We adjusted for general demographic data, e.g., sex of the child and education of parents as proxy for socioeconomic status which are common confounders of health-related processes. Additionally, we controlled for alcohol consumption during pregnancy and smoking---both variables were linked to immunological markers in past research. However, we did not consider the effect of breastfeeding as a potentially immunomodulatory variable ([@B35]).

The LISA study is one of the largest population-based cohort studies in children with information on immune status. We were able to investigate the association of vaccinations, infections, and exposures during pregnancy on the immune response in a single dataset. In contrast to previous epidemiological studies on NSE, we used a very broad approach and assessed the impact of diverse co-variables to find out whether previously unreported associations exist. To our knowledge, we were the first investigating the NSE of the individual infection history of children on the humoral immune response. Some of our findings in this exploratory study were in line with already published data. Nevertheless, to our knowledge some observations have not been discussed in the literature before. While the number of observed significant associations was larger than the number expected, some associations were due to chance. For the correction of possible false positive findings due to multiple testing, we did not consider strategies to adjust *p*-values, such as Bonferroni correction; instead we performed a permutation test. Bonferroni correction focusses on identifying truly significant associations but is overly conservative when applied to medium to large numbers of tests and could also increasing Type II (i.e., false negative) error ([@B36]). The purpose of using permutation tests was the question of assessing whether there are overall true statistical associations in the data, without pointing out which of the associations are true. In general, permutation-based tests have become widely accepted in studied involving multiple statistical testing ([@B37]). In contrast, the multivariable analysis was purely exploratory and should only inform further research.

Conclusion {#s5}
==========

In conclusion, our results indicate that for some routine childhood vaccinations and the individual infection history of a child there are associations with selective modulation of the humoral immune response in early childhood. This might be linked to the previously described changes in morbidity and mortality rates associated with NSE of certain vaccines. However, there is still need for further studies to better understand underlying immunological mechanisms involved in NSE of vaccines and the effects of the individual infection history. Long-term consequences of a better understanding of NSE could be the adjustment of current vaccination strategies in order to support the optimal maturation of the immune system.
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